Nature Outlook |

Precision oncology

The aim of precision oncology is to develop treatments that target the molecular characteristics of an individual’s tumour. This tailored approach to cancer care could be transformative, but currently only a select few people with cancer are benefitting.

This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.

Features and comment

Cancer treatments that target the characteristics of an individual's tumour could have a wider impact.

Outlook | | Nature

Targeted treatments for children, a fresh approach to protein analysis and other highlights from clinical trials and laboratory studies.

Outlook | | Nature

The current technique requires a person’s own cells, but using the cells of healthy donors could allow more people to benefit.

Outlook | | Nature

Some people with cancer are already benefiting from drugs that target genetic features regardless of the tissue involved. But these early successes could be the exceptions.

Outlook | | Nature

Janssen’s Craig Tendler talks to Nature about how data collected by the company after a drug is approved can be used to improve treatment.

Outlook | | Nature

More from Nature Research

The flagship paper of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium describes the generation of the integrative analyses of 2,658 cancer whole genomes and their matching normal tissues across 38 tumour types, the structures for international data sharing and standardized analyses, and the main scientific findings from across the consortium studies.

Article | Open Access | | Nature

Precision medicine approaches to the treatment of cancer are largely reliant on genomic analysis alone. In this Perspective the authors provide a rationale for the incorporation of analysis of the proteome, which is a rich source of biological heterogeneity, into the treatment and management of patients with cancer.

Perspective | | Nature Reviews Clinical Oncology

In the past few years, the use of data from the real world has garnered increasing interest; however, studies using real-world data (RWD) should not be used as substitutes for clinical trials. The authors of this Review explore the quality of RWD, provide a framework for the use of RWD and draw attention to the methodological pitfalls inherent to using RWD.

Review Article | | Nature Reviews Clinical Oncology

The use of allogeneic chimeric antigen receptor T cells from donors has many potential advantages over autologous approaches, such as immediate availability, standardization and the possibility of redosing or combination. This Review analyses the different sources of T cells and technological approaches to produce optimal allogeneic chimeric antigen receptor T cells with limited potential for graft-versus-host disease and increased persistence.

Review Article | | Nature Reviews Drug Discovery